Loading...
•
Dec 31, 2020
Immunome Q4 2020 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
Key Takeaways
Immunome reported its Q4 and full year 2020 financial results, highlighting a transformational period marked by a successful NASDAQ IPO that raised $44.9 million in gross proceeds. The company is advancing its IMM-ONC-01 program into IND-enabling studies and expects to provide development program updates in the second quarter of 2021.
Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing (IMM-BCP-01).
Advanced proprietary antibody against IL-38 into IND-enabling studies (IMM-ONC-01).
Raised $44.9 million in gross proceeds in NASDAQ IPO.
Program updates expected in 2Q 2021.
Immunome
Immunome
Forward Guidance
Immunome anticipates providing development program updates in Q2 2021 and intends to file INDs for both IMM-BCP-01 and IMM-ONC-01 in 2021.
Positive Outlook
- Development program updates expected in the second quarter of 2021.
- Filing INDs for both IMM-BCP-01 and IMM-ONC-01 in 2021.
- Prospects for both of current development programs.
- Confidence in discovery engine to move one to two new candidates into IND-enabling studies per year.
- Isolation of antibodies capable of neutralizing SARs-CoV-2 variants in pseudovirus testing as part of IMM-BCP-01 program.
Challenges Ahead
- Impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones.
- Ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones.
- Timing and effectiveness of any antibody therapeutics which may be developed by Immunome.
- Ability to fund operations.
- Risks and uncertainties associated with Immunome’s business